Michael J Fox Foundation chooses platform to help with Parkinson's research

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Parkinson's disease neurodegenerative diseases CNS Clinical trial Patient centricity Clinical research

H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.

H1 says it can improve research initiatives and education which will help clinical trial teams. The company also notes that just under one million people in the US and six million worldwide are affected by PD and that continuing research is essential. It also discovered that every six minutes, someone in the US is diagnosed with the disease and believes therefore it is ‘imperative to reach out to those living with the disease’ to provide opportunities to take part in research and remain informed about advancements in treatment.

H1 says that the first step in this process is identifying the physicians who are treating PD and gaining a deep understanding of their patient populations. The company says this knowledge will allow for research and clinical trial teams to partner with a more representative population, paving the way for more impactful outcomes in PD research. By partnering with these providers, MJFF aims to educate patients on available studies and encourage participation.

Maggie Kuhl, MJFF vice president of research engagement, said: “Engaging diverse populations in clinical studies is critical to advancing treatment and care for all those living with PD.

“We know that many study volunteers learn of these opportunities from their treating physician. More information on who is treating people with PD – and especially populations traditionally underrepresented in research – can help us deliver the information and tools that will enable those conversations and lead to greater representation in studies. H1 Trial Landscape is a valuable tool to identify and connect with those providers.”

H1 says its platform represents more than 10 million healthcare providers globally and more than 420,000 clinical trials. MJFF believes it can support its mission of increasing knowledge about the lived experience of Parkinson's disease, engaging patients in research and trials, and supporting the development of new treatments and a cure.

The Michael J. Fox Foundation says it will use Trial Landscape to streamline its search for physicians who are actively treating Parkinson's disease and gather comprehensive information on their patient populations and treatment approaches.

The company and MJFF believe this data will be invaluable in identifying potential contacts for marketing efforts, allowing the Foundation to effectively reach out to physicians who are most likely to be interested in their initiatives.

Additionally, they say Trial Landscape will help the Foundation gain insights into underrepresented patient populations to better understand the specific needs and challenges faced by these groups and develop targeted strategies to support them effectively.

“We are proud to partner with The Michael J. Fox Foundation in their mission of helping the world better understand Parkinson’s and support patients living with the disease,” said Ariel Katz, CEO and co-founder, H1.

“As a result of our partnership, the Foundation will have access to our extensive global database of healthcare providers and clinical trials to improve how they connect with physicians and patients, and ultimately make strides in one day finding a cure.”

The company claims its data platform fuels a ‘robust enterprise product suite’ that supports the advancement of healthcare innovation and equity. 

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more